Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human βA-T87Q-globin gene is a modified version of the adult β-globin gene (HBB) with a threonine to glutamine substitution at position 87. This modification confers anti-sickling properties, making it a therapeutic target for hemoglobinopathies such as sickle cell disease and transfusion-dependent β-thalassemia. It functions by disrupting HbS polymerization and restoring/augmenting normal hemoglobin function.
Inhibits HbS polymerization, restoring effective oxygen transport by producing functional hemoglobin tetramers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human βA-T87Q-globin (βA-T87Q-globin).